Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34+ cell dose

Bone Marrow Transplantation volume 27, pages 791–800 (2001)Cite this article

Abstract

We have performed univariate and multivariate analysis to determine the factors that affect the kinetics of neutrophil and platelet recovery in 546 recipients of T cell-depleted (TCD) marrow allografts. All patients received marrow depleted of mature CD3+ T cells by complement-mediated lysis using T10B9-1A3 (n = 489) or Muromonab-Orthoclone OKT3 (n = 57) monoclonal antibodies. Neutrophil engraftment to 0.5 × 109/1 and platelet engraftment to 20 × 109/l were assessed as endpoints. Factors significantly affecting neutrophil or platelet engraftment in the univariate analysis included patient age, T cell dose, anti-thymocyte globulin use, gender, diagnosis at transplant, CMV serostatus, HLA mismatch, CD34 cell dose (n = 249), and growth factor use and type. These variables were included in the multivariate Cox proportional hazards regression model. The results showed that a faster rate of neutrophil engraftment was independently associated with CD34+ cell dose ⩾5 × 106/kg and most strongly with growth factor administration. Faster platelet engraftment was associated with transplantation for chronic leukemia, CD34+ cell dose ≥2 × 106/kg, an HLA matched related donor, and the absence of growth factor use. G-CSF had a higher relative risk (RR) of enhancing neutrophil engraftment than GM-CSF and significantly delayed platelet engraftment. The combined use of G-CSF + GM-CSF was similar to G-CSF alone. The enhancing effect of G-CSF for neutrophil recovery was most striking for patients who engrafted to 0.5 × 109/1 at or before day 12 (RR = 9.5, P < 0.0001) compared to patients who received no growth factor. Conversely, the delaying effect of G-CSF on platelet engraftment was strongest for patients engrafting on or before day 25 (RR = 0.4, P = 0.0004). Of the independent variables affecting engraftment kinetics in recipients of TCD marrow allografts only growth factor, and to a limited extent, CD34+ cell dose can be controlled by the clinician. A higher CD34+ cell dose enhances the rate of both neutrophil and platelet engraftment whereas for G-CSF the benefits of myeloid growth factor use in enhancing neutrophil recovery may be partly offset by a delay in platelet engraftment. Bone Marrow Transplantation (2001) 27, 791–800.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Champlin RE, Passweg JR, Zhang MJ et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities Blood 2000 95: 3996–4003

    CAS  PubMed  Google Scholar 

  2. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ . Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia Transplantation 1987 43: 842–847

    Article  CAS  PubMed  Google Scholar 

  3. Lazarus HM . Recombinant cytokines and hematopoietic growth factors in allogeneic and autologous bone marrow transplantation Cancer Treat Res 1997 77: 255–301

    Article  CAS  PubMed  Google Scholar 

  4. Bishop M, Tarantolo S, Geller R et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation Blood 2000 96: 80–85

    CAS  PubMed  Google Scholar 

  5. Bernstein SH, Nademanee AP, Vose JM et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation Blood 1998 91: 3509–3517

    CAS  PubMed  Google Scholar 

  6. Powles R, Smith C, Milan S et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial Lancet 1990 336: 1417–1420

    Article  CAS  PubMed  Google Scholar 

  7. Nemunaitis J, Buckner CD, Appelbaum FR et al. Phase I/II trial of recombinant human granulocyte–macrophage colony-stimulating factor following allogeneic bone marrow transplantation Blood 1991 77: 2065–2071

    CAS  PubMed  Google Scholar 

  8. Nemunaitis J, Rosenfeld CS, Ash R et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation Bone Marrow Transplant 1995 15: 949–954

    CAS  PubMed  Google Scholar 

  9. Martin-Algarra S, Bishop MR, Tarantolo S et al. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis Exp Hematol 1995 23: 1503–1508

    CAS  PubMed  Google Scholar 

  10. Shimazaki C, Oku N, Uchiyama H et al. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation Bone Marrow Transplant 1994 13: 271–175

    CAS  PubMed  Google Scholar 

  11. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial J Clin Oncol 1995 13: 1323–1327

    Article  CAS  PubMed  Google Scholar 

  12. Linch DC, Milligan DW, Winfield DA et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial Br J Haematol 1997 99: 933–938

    Article  CAS  PubMed  Google Scholar 

  13. Kawano Y, Takaue Y, Mimaya J et al. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT Blood 1998 92: 4040–4046

    CAS  PubMed  Google Scholar 

  14. Bensinger W, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBPCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation Br J Haematol 1994 87: 825–831

    Article  CAS  PubMed  Google Scholar 

  15. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells J Clin Oncol 1995 13: 2547–2555

    Article  CAS  PubMed  Google Scholar 

  16. Henon P, Sovalat H, Becker M et al. Primordial role of CD34+ 38-cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation Br J Haematol 1998 103: 568–581

    Article  CAS  PubMed  Google Scholar 

  17. De Witte T, Gratwohl A, Van Der Lely N et al. Recombinant human granulocyte–macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation Blood 1992 79: 1359–1365

    CAS  PubMed  Google Scholar 

  18. Lee SJ, Weller E, Alyea EP et al. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation Blood 1998 92: 2725–2729

    CAS  PubMed  Google Scholar 

  19. Ash RC, Casper JT, Chitambar CR et al. Successful allogeneic marrow transplantation from closely HLA-matched unrelated donors using T-cell depletion New Engl J Med 1991 322: 485–494

    Article  Google Scholar 

  20. Margolis D, Camitta B, Pietryga D et al. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults Br J Haematol 1996 94: 65–72

    Article  CAS  PubMed  Google Scholar 

  21. Baxter-Lowe LA, Eckels DD, Ash R et al. Future directions in selection of donors for bone marrow transplantation: role of oligonucleotide genotyping Transplant Proc 1991 23: 1699–1700

    CAS  PubMed  Google Scholar 

  22. Baxter-Lowe LA, Keever C, Dinauer D et al. Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients Transplant Proc 1995 27: 1377–1378

    CAS  PubMed  Google Scholar 

  23. Keever CA, Leong N, Cunningham I et al. HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation Bone Marrow Transplant 1994 14: 137–145

    CAS  PubMed  Google Scholar 

  24. Sutherland DR, Keating A, Nayar R et al. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry Exp Hematol 1994 22: 1003–1010

    CAS  PubMed  Google Scholar 

  25. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering J Hematother 1996 5: 213–226

    Article  CAS  PubMed  Google Scholar 

  26. Kawanishi Y, Flomenberg N, Cook-Craig A et al. A new limiting dilution culture system for the detection of T cell subsets in T cell-depleted marrow grafts J Hematother 1996 5: 485–495.

    Article  CAS  PubMed  Google Scholar 

  27. Simmons PJ, Przepiorka D, Thomas ED, Torok-Storb B . Host origin of marrow stromal cells following allogeneic bone marrow transplantation Nature 1987 328: 429–432

    Article  CAS  PubMed  Google Scholar 

  28. Champlin RE, Horowitz MM, van Bekkum DW et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results Blood 1989 73: 606–613

    CAS  PubMed  Google Scholar 

  29. McCann SR, Bacigalupo A, Gluckman E et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group Bone Marrow Transplant 1994 13: 233–237

    CAS  PubMed  Google Scholar 

  30. Anasetti C, Rybka W, Sullivan K et al. Graft-v-host disease is associated with autoimmune-like thrombocytopenia Blood 1989 43: 1054–1058

    Google Scholar 

  31. Faucher C, Le Corroller AG, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study Bone Marrow Transplant 1996 17: 533–536

    CAS  PubMed  Google Scholar 

  32. Bence-Bruckler I, Bredeson C, Atkins H et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post autologous stem cell transplantation Bone Marrow Transplant 1998 22: 965–969

    Article  CAS  PubMed  Google Scholar 

  33. Torres Gomez A, Jimenez MA, Alvarez MA et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study Ann Hematol 1995 71: 65–70

    Article  CAS  PubMed  Google Scholar 

  34. Ciernik IF, Schanz U, Gmur J . Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial Bone Marrow Transplant 1999 24: 147–151

    Article  CAS  PubMed  Google Scholar 

  35. Lee KH, Lee JH, Choi SJ et al. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation Bone Marrow Transplant 1999 24: 591–599

    Article  CAS  PubMed  Google Scholar 

  36. Lazarus HM, Rowe JM . Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation Blood Rev 1994 8: 169–178

    Article  CAS  PubMed  Google Scholar 

  37. Schriber JR, Chao NJ, Long GD et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation Blood 1994 84: 1680–1684

    CAS  PubMed  Google Scholar 

  38. Saarinen UM, Hovi L, Juvonen E et al. Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children Med Pediatr Oncol 1996 26: 380–386

    Article  CAS  PubMed  Google Scholar 

  39. Berger C, Bertz H, Schmoor C et al. Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors Bone Marrow Transplant 1999 23: 983–990

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Madero L, Diaz MA, Ortega JJ et al. Recombinant human granulocyte–macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia Haematologica 1999 84: 133–137

    CAS  PubMed  Google Scholar 

  41. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit J Clin Oncol 1994 12: 661–670

    Article  CAS  PubMed  Google Scholar 

  42. Vose JM, Bierman PJ, Ruby E et al. Use of continuous infusion granulocyte–macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies Bone Marrow Transplant 1996 17: 951–956

    CAS  PubMed  Google Scholar 

  43. Weisdorf DJ, Verfaillie CM, Davies SM et al. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte–macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF Blood 1995 85: 3452–3456

    CAS  PubMed  Google Scholar 

  44. Sreenan C, Osiovich H . Myeloid colony-stimulating factors: use in the newborn Arch Pediatr Adolesc Med 1999 153: 984–988

    Article  CAS  PubMed  Google Scholar 

  45. Jansen J, Thompson EM, Hanks S et al. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF Bone Marrow Transplant 1999 23: 1251–1256

    Article  CAS  PubMed  Google Scholar 

  46. Souza LM, Boone TC, Gabrilove J et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells Science 1986 232: 61–65

    Article  CAS  PubMed  Google Scholar 

  47. Ebihara Y, Xu M, Manabe A et al. Exclusive expression of G-CSF receptor on myeloid progenitors in bone marrow CD34+ cells Br J Haematol 2000 109: 153–161

    Article  CAS  PubMed  Google Scholar 

  48. Xu S, Höglund M, Hkansson L, Venge P . Granulocyte colony-stimulating factor (G-CSF) induces the production of cytokines in vivo Br J Haematol 2000 108: 848–853

    Article  CAS  PubMed  Google Scholar 

  49. Armitage J . Emerging applications of recombinant humangranulocyte–macrophage colony-stimulating factor Blood 1998 92: 4491–4508

    CAS  PubMed  Google Scholar 

  50. Weaver C, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy Blood 1995 86: 3961–3969

    CAS  PubMed  Google Scholar 

  51. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy BoneMarrow Transplant 1993 11: 369–374

    CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge the assistance of Claudia Kabler-Babbitt and Diane Bauer, data keepers for the adult and pediatric BMT programs, respectively, for gathering the data needed for this report.

Author information

Authors and Affiliations

  1. Bone Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, WI, USA

    CA Keever-Taylor, C Bredeson, DA Margolis, WH Burns & DH Vesole

  2. Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA

    JP Klein & D Eastwood

Authors
  1. CA Keever-Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JP Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Eastwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Bredeson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. DA Margolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. WH Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. DH Vesole
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keever-Taylor, C., Klein, J., Eastwood, D. et al. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34+ cell dose. Bone Marrow Transplant 27, 791–800 (2001). https://doi.org/10.1038/sj.bmt.1702872

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702872

Keywords

This article is cited by

Search

Advanced search

Quick links